hepatitis delta

In this episode, Nancy Reau, MD, and her patient discuss opportunities to optimize care for people living with hepatitis B virus and hepatitis delta virus, including:

• The importance of patient education along the care continuum
• Ensuring smooth transitions of care and communication between medical teams
• Screening hepatitis delta in persons with chronic hepatitis B
• Managing hepatitis delta, including considerations for clinical trials
• Promoting patient advocacy

Presenter: 

Nancy Reau, MD
Professor of Medicine 
Chief, Section of Hepatology
Associate Director, Solid Organ Transplantation
Richard B. Capps Chair of Hepatology
Rush University Medical Center
Chicago, Illinois

Content based on an online CME program supported by an independent educational grant from Gilead Sciences, Inc.

Link to full program: bit.ly/3SrMuGO

Get access to all of our new podcasts by subscribing to the CCO Infectious Disease Podcast on Apple Podcasts, Google Podcasts, or Spotify.

In this episode, Douglas Dieterich, MD, leads a panel discussion with Camilla S. Graham, MD, MPH, and Robert Wong, MD, MS, to consider advantages and barriers to universal screening for chronic HBV infection and universal HDV screening in adults with HBV in the United States. Topics include:

• Updated CDC recommendations for one-time universal screening for HBV
• Addressing patient-, provider-, and system-level barriers to universal HBV screening
• Best practices for implementation of HDV screening

Presenters:

Douglas Dieterich, MD
Director, Institute for Liver Medicine

Professor of Medicine

Division of Liver Diseases

Mount Sinai School of Medicine

New York, New York

Camilla S. Graham, MD, MPH
Co-Director, Viral Hepatitis Clinic
Division of Infectious Diseases
Beth Israel Deaconess Medical Center
Harvard Medical School
Boston, Massachusetts

Robert Wong, MD, MS 
Clinical Associate Professor
Division of Gastroenterology and Hepatology
Stanford University School of Medicine
Palo Alto, California

Link to full program:
https://bit.ly/3TuqFHI

Link to the slides: 
https://bit.ly/4atS42z

In this episode, Douglas Dieterich, MD, leads a panel discussion with Camilla S. Graham, MD, MPH, and Robert Wong, MD, MS, to consider advantages and barriers to universal screening for chronic HBV infection and universal HDV screening in adults with HBV in the United States. Topics include:

• Updated CDC recommendations for one-time universal screening for HBV
• Addressing patient-, provider-, and system-level barriers to universal HBV screening
• Best practices for implementation of HDV screening

Presenters:

Douglas Dieterich, MD
Director, Institute for Liver Medicine

Professor of Medicine

Division of Liver Diseases

Mount Sinai School of Medicine

New York, New York

Camilla S. Graham, MD, MPH
Co-Director, Viral Hepatitis Clinic
Division of Infectious Diseases
Beth Israel Deaconess Medical Center
Harvard Medical School
Boston, Massachusetts

Robert Wong, MD, MS 
Clinical Associate Professor
Division of Gastroenterology and Hepatology
Stanford University School of Medicine
Palo Alto, California

Link to full program:
https://bit.ly/3TuqFHI

Link to the slides: 
https://bit.ly/4atS42z

In this episode, Douglas Dieterich, MD, leads a panel discussion with Camilla S. Graham, MD, MPH, and Robert Wong, MD, MS, to consider advantages and barriers to universal screening for chronic HBV infection and universal HDV screening in adults with HBV in the United States. Topics include:

• Updated CDC recommendations for one-time universal screening for HBV
• Addressing patient-, provider-, and system-level barriers to universal HBV screening
• Best practices for implementation of HDV screening

Presenters:

Douglas Dieterich, MD
Director, Institute for Liver Medicine

Professor of Medicine

Division of Liver Diseases

Mount Sinai School of Medicine

New York, New York

Camilla S. Graham, MD, MPH
Co-Director, Viral Hepatitis Clinic
Division of Infectious Diseases
Beth Israel Deaconess Medical Center
Harvard Medical School
Boston, Massachusetts

Robert Wong, MD, MS 
Clinical Associate Professor
Division of Gastroenterology and Hepatology
Stanford University School of Medicine
Palo Alto, California

Link to full program:
https://bit.ly/3TuqFHI

Link to the slides: 
https://bit.ly/4atS42z

In this episode, Stefan Zeuzem, MD, discusses new data on viral hepatitis presented at EASL 2023, including:

• Hepatitis B virus
  • Durability of response with bepirovirsen
  • HBsAg loss with siRNA VIR-2218 combined with either VIR-3434 (novel monoclonal antibody) or pegIFN-alfa
• Hepatitis delta virus
  • 96-week follow-up of immediate vs delayed bulevirtide
  • Off-treatment response for lonafarnib + ritonavir ± pegIFN-alfa 
  • Safety and efficacy outcomes with siRNA JNJ-3989 + nucleos(t)ide analogue
• Hepatitis C virus
  • Collaborative service at opiate substitution treatment clinic to improve linkage to care in Ireland
  • Nurse-led test-and-treat program to increase screening and diagnosis at female prisons in the United Kingdom
  • FIND-C study using machine learning to improve screening-to-diagnosis ratio using clinical factors and social determinants of health

Presenter:

Stefan Zeuzem, MD
Professor of Medicine 
Chief, Department of Medicine 
JW Goethe University Hospital 
Frankfurt, Germany

Link to full program: 

https://bit.ly/3JQQj3J

In this episode, Tarik Asselah, MD, PhD, and Ira Jacobson, MD, provide expert insight on HDV screening, diagnosis, and management, including:

• Approach to screening
• Barriers to screening (eg, test availability)
• Disease progression and complications
• Differentiating between coinfection and superinfection
• Approach to treatment (eg, whom to treat and when, treatment options, considerations for combination therapy)
• Management of patients with decompensated cirrhosis
• Surrogate markers to measure treatment success
• Role of correcting thrombocytopenia before initiating therapy

Faculty:

Tarik Asselah, MD, PhD
Professor of Medicine 
Department of Hepatology
Hôpital Beaujon
Université de Paris
Clichy, France

Ira Jacobson, MD
Professor of Medicine
NYU School of Medicine
Director of Hepatology
Division of Gastroenterology and Hepatology
NYU Langone Health
New York, New York

Link to full program: https://bit.ly/3yp1Lxf

In this episode, Nancy Reau, MD, and Heiner Wedemeyer, MD, provide expert insight on HDV management, including:

• Use of noninvasive imaging or biopsy for staging liver disease
• Screening for hepatocellular carcinoma
• HBV treatment
• Role of comedications (eg, erythropoietin, eltrombopag)
• Approach to complex cases, such as patients with:
  • Significant fibrosis and low HDV RNA levels
  • Hepatitis delta antibody positivity, but HDV RNA negativity
  • HIV coinfection
  • Decompensated or recently decompensated cirrhosis

Faculty:

Nancy Reau, MD
Professor of Medicine
Chief, Section of Hepatology
Associate Director, Solid Organ Transplantation
Richard B. Capps Chair of Hepatology
Rush University Medical Center
Chicago, Illinois

Heiner Wedemeyer, MD
Professor and Chairman
Department of Gastroenterology, Hepatology and Endocrinology 
Hannover Medical School
Hannover, Germany

Link to full program: 
http://bit.ly/3yp1Lxf

In this episode, Tatyana Kushner, MD, MSCE, and Stefan Zeuzem, MD, address key considerations when screening, diagnosing, and treating patients with HDV, such as:

• Barriers to HDV screening, including limitations to AASLD guideline recommendations
• Use of double reflex testing to improve HDV diagnosis
• Considerations for repeat HDV testing in patients who are HBsAg positive who previously tested negative for HDV
• Updated CDC recommendations for HBV screening for all adults using a triple panel test 
• Staging advanced liver disease in patients with HDV
• Indications for HDV treatment, including patients with low ALT levels and advanced or progressive liver disease
• Treatment landscape for HDV
• Personal experiences with use of pegylated interferon for HDV treatment, including considerations for use in patients with compensated cirrhosis
• Updates on novel HDV therapies, including:
  • Summary of efficacy data on bulevirtide from clinical trials
  • Interpretation of results from D-LIVR, a phase III trial assessing the safety and efficacy of lonafarnib 

Link to full program: 
bit.ly/3yp1Lxf

In this episode, Maria Buti, MD, and Richard H. Davis, PA-C, address key considerations when screening, diagnosing, and treating patients with hepatitis delta virus (HDV), such as:

• Barriers to screening 
• HDV screening based on patient risk factors 
• Universal screening for all patients with positive hepatitis B surface antigen (HBsAg)
• Reflex testing 
• Availability of commercial testing
• Monitoring suggestions in HBsAg positive and HDV antibody positive patients with negative HDV RNA
• Limitations to evaluating advanced fibrosis in patients with HDV
• Data on novel HDV therapies (eg, bulevirtide and lonafarnib)
• Extending HDV therapy (eg, peginterferon) based on treatment response
• Stopping rules (eg, HDV RNA negativity, HBsAg loss) for discontinuing HDV therapy

Faculty:

Maria Buti, MD
Professor of Medicine
Hospital Universitario Vall d’Hebron
Barcelona, Spain

Richard H. Davis, PA-C
Senior PA
Gastroenterology
University of Florida
UF Health
Gainesville, Florida

Link to full program: 
http://bit.ly/3yp1Lxf

In this episode, Stefan Zeuzem, MD, discusses new viral hepatitis data from AASLD 2022, including:

• Hepatitis B
• Prevention of HBV vertical transmission when HBIg is unavailable
• Therapeutic vaccination for HBV cure
• Antiviral therapy to prevent HCC in patients with CHB in the indeterminate phase
• Hepatitis delta
• HDV prevalence in ethnically diverse, urban, safety-net populations
• Bulevirtide ± pegIFN-α2a for chronic HDV in the French cATU study
• Bulevirtide monotherapy for patients with HDV and compensated cirrhosis in the HEP4Di study
• HDV functional cure with lonafarnib-based therapy
• Hepatitis C
• Integrated community HCV service for PWUD: the ITTREAT study
• Helios-3 study of treatment of people with HCV by specialists or nonspecialists
• Risk of HCC after SVR in patients with HCV

Presenter:

Stefan Zeuzem, MD
Professor of Medicine
Chief, Department of Medicine I 
JW Goethe University Hospital 
Frankfurt, Germany

Follow along with the downloadable slideset at: 
https://bit.ly/3FxIOwZ

Link to full program: 
https://bit.ly/3Y1tD6f

In this episode, Nancy Reau, MD, shares her thoughts on the most practice-changing viral hepatitis data from AASLD 2022, including:

• Novel therapeutics for HBV
• HCV management strategies
• HDV screening and linkage to care
• Fatty liver disease in persons with viral hepatitis
• Use of statins to decrease morbidity and mortality in persons with liver disease

Presenter:

Nancy Reau, MD
Professor of Medicine
Chief, Section of Hepatology
Associate Director
Solid Organ Transplantation
Richard B. Capps Chair of Hepatology
Rush University Medical Center
Chicago, Illinois

Link to full program: 
https://bit.ly/3Y1tD6f

You can think of the “D” in HDV as standing for difficult, disadvantaged, and dangerous. Hepatitis delta virus (HDV) is difficult to diagnose, is often diagnosed in disadvantaged patient populations, and leads to dangerous sequelae.

Listen as Dr. Kosh Agarwal and Dr. Graham R. Foster and discuss challenges and opportunities for linking patients to care after a positive test for HDV.

Presenters:

Kosh Agarwal, MD
Consultant Hepatologist and Transplant Physician
Institute of Liver Studies
King's College Hospital NHS Foundation Trust
London, United Kingdom

Graham R. Foster, FRCP, PhD
Professor of Hepatology
The Liver Unit
Consultant Hepatologist
Queen Mary University of London
London, United Kingdom

Link to full program:
https://bit.ly/3tlxa0H

In this episode, Stefan Zeuzem, MD, discusses new viral hepatitis data from EASL 2022, including:

• Novel HBV therapeutics, including the REEF-2, B-Clear, and SAVE-1 studies
• HBV cure from the Everest Project in China
• HDV therapeutics from MYR301 and a study of bulevirtide in patients with cirrhosis and portal hypertension
• HCV retreatment in patients with prior direct-acting antiviral therapy failure

Presenter: 

Stefan Zeuzem, MD
Professor of Medicine
Chief, Department of Medicine I 
JW Goethe University Hospital 
Frankfurt, Germany

Follow along with the downloadable slideset at:
https://bit.ly/3yJAruD

Link to full program: 
https://bit.ly/3AjCNBC

In this episode, Nancy Reau, MD, discusses new viral hepatitis data from EASL 2022, including:

• Novel therapeutics for HBV
• Therapeutic vaccination for HBV
• Emerging treatment options for HDV
• HCV care cascade
• HCC monitoring after HCV cure

Presenter: 

Nancy Reau, MD
Professor of Medicine
Chief, Section of Hepatology
Associate Director, Solid Organ Transplantation
Richard B. Capps Chair of Hepatology
Rush University Medical Center
Chicago, Illinois

Follow along with the downloadable slideset at: 
https://bit.ly/3yJAruD

Link to full program:
https://bit.ly/3IeUapm

Hepatitis delta virus (HDV) is the most severe form of viral hepatitis, yet many patients go undiagnosed. Increasing HDV awareness is an important step to correct this and ensure that at-risk patients receive screening and then treatment and monitoring following a positive test. Hear Grace LH Wong, MD, and Ming-Lung Yu, MD, PhD, discuss a call to action to increase healthcare professional and patient awareness of HDV. 

Presenters: 

Grace LH Wong, MD
Professor
Director, Medical Data Analytics Centre (MDAC)
Deputy Director, Center for Liver Health
Assistant Dean (Learning Experience), Faculty of Medicine
The Chinese University of Hong Kong
Honorary Consultant
Division of Gastroenterology and Hepatology
Department of Medicine and Therapeutics
Prince of Wales Hospital
Hong Kong

Ming-Lung Yu, MD, PhD
Chair Professor
Hepatobiliary Division
Department of Internal Medicine and Hepatitis Center
Kaohsiung Medical University
Visiting Staff
Hepatobiliary Division
Department of Internal Medicine
Kaohsiung Medical University Hospital
Kaohsiung City, Taiwan

Link to full program: 
https://bit.ly/3tlxa0H

Hepatitis delta virus (HDV) is the most severe form of viral hepatitis and warrants new treatment options for better efficacy and tolerability. In part 2 of this 2-part podcast series, hear Heiner Wedemeyer, MD, and Cihan Yurdaydin, MD, discuss their thoughts on new and emerging treatment options for HDV and rational use of these new agents. Their discussion includes:

• Assembly inhibitors (eg, lonafarnib)
• Entry inhibitors (eg, bulevirtide)
• Interferon lambda
• Nucleic acid polymers
• Small interfering RNA (siRNA) agents

Presenters: 

Heiner Wedemeyer, MD
Professor and Chairman
Department of Gastroenterology, Hepatology, and Endocrinology
Hannover Medical School
Hannover, Germany

Cihan Yurdadin, MD
Professor and Chief
 Department of Gastroenterology and Hepatology
Koç University Medical School
Istanbul, Turkey

Link to full program:
https://bit.ly/365VUlG

Hepatitis delta virus (HDV) only exists in patients with hepatitis B virus (HBV) coinfection. In part 1 of this 2-part podcast series, hear Heiner Wedemeyer, MD, and Cihan Yurdaydin, MD, discuss their thoughts on serologic testing for both HDV and HBV and steps to take in monitoring, treating, and reassessing HBV in patients coinfected with HDV.

Presenters:

Heiner Wedemeyer, MD
Professor and Chairman
Department of Gastroenterology, Hepatology, and Endocrinology
Hannover Medical School
Hannover, Germany

Cihan Yurdaydin, MD
Professor and Chief, Department of Gastroenterology and Hepatology
Koç University Medical School
Istanbul, Turkey

Link to full program:
https://bit.ly/365VUlG

Treatment options for hepatitis delta virus (HDV) are lacking, but many exciting agents are under investigation. Hear Drs Nancy Reau and Stefan Zeuzem discuss their thoughts on up-and-coming agents for treating HDV, and explore what questions need answering to most effectively use currently available and emerging therapies, which include:

• Bulevirtide
• Interferon λ
• Lonafarnib

Presenters:

Nancy Reau, MD
Professor of Medicine
Chief, Section of Hepatology
Associate Director, Solid Organ Transplantation
Richard B. Capps Chair of Hepatology
Rush University Medical Center
Chicago, Illinois

Stefan Zeuzem, MD
Professor of Medicine
Chief, Department of Medicine I
JW Goethe University Hospital
Frankfurt, Germany

Link to full program:
https://bit.ly/3tlxa0H

In this episode, Robert G. Gish, MD, and Pietro Lampertico, MD, PhD, share lessons learned in the care of patients coinfected with hepatitis B virus and hepatitis delta virus (HDV), including:

• Burden of HDV infection
• Chronic HDV infection and comorbidities
• Impact of COVID-19 on care of patients with chronic hepatitis B
• Screening for HDV and which assays to use
• Screening for viral hepatitis at a COVID-19 vaccination site

Presenters:

Robert G. Gish, MD, FAASLD, AGAF, FAST
Professor of Medicine
Loma Linda University
Loma Linda, California
Clinical Professor
University of Nevada Reno School of Medicine
Reno, Nevada
University of California Skaggs School of Pharmacy and Pharmaceutical Sciences
San Diego, California
Medical Director
Hepatitis B Foundation
Washington, DC

Pietro Lampertico, MD, PhD
Professor of Gastroenterology
Director, Division of Gastroenterology and Hepatology
IRCCS Ca Granda Policlinico Hospital
University of Milan
Milan, Italy

Follow along with the slides at:
https://bit.ly/3HQ6dZ5

Link to full program: 
https://bit.ly/3Bgyd5I

Hepatitis delta is the most severe form of viral hepatitis, and many patients remain undiagnosed. In this episode, Maria Buti, MD, and Robert G. Gish, MD, discuss the prevalence and severity of hepatitis delta. Hear their personal experiences from the clinic and their call to action for universal screening of patients with hepatitis B for coinfection with hepatitis delta.

Presenters:
Maria Buti, MD
Professor of Medicine
Hospital Universitario Vall d'Hebron
Barcelona, Spain

Robert G. Gish, MD
Professor of Medicine
Loma Linda University
Loma Linda, California
Medical Director
Hepatitis B Foundation
Washington, DC

Link to full program:
https://bit.ly/3E9xKSx